{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:27:12Z","timestamp":1793698032048,"version":"4.5.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clml.2026.07.009","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T15:35:05Z","timestamp":1784388905000},"page":"e1202-e1210.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Geographic Variation and Inequities in Burden and Access to CAR T-Cell Therapies for Multiple Myeloma in the US"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0639-3768","authenticated-orcid":false,"given":"Brandon J.","family":"Blue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-5350","authenticated-orcid":false,"given":"Andrew K.","family":"ElHabr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Derman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0047-7453","authenticated-orcid":false,"given":"Avik","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizi","family":"Elsisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian","family":"Farajkhah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8720-0280","authenticated-orcid":false,"given":"Turgay","family":"Ayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attaya","family":"Suvannasankha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clml.2026.07.009_bib0001","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.07.009_bib0002","doi-asserted-by":"crossref","unstructured":"Suzuki T, Iida S Advances and future perspectives in chimeric antigen receptor T-cell and bispecific antibody therapies for multiple myeloma. J Clin Exp Hematop. 65(4):225-237. 10.3960\/jslrt.25038.","DOI":"10.3960\/jslrt.25038"},{"issue":"5","key":"10.1016\/j.clml.2026.07.009_bib0003","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"8","key":"10.1016\/j.clml.2026.07.009_bib0004","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.07.009_bib0005","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ijrobp.2015.12.012","article-title":"Association between geographic access to cancer care and receipt of radiation therapy for rectal cancer","volume":"94","author":"Lin","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.clml.2026.07.009_bib0006","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","article-title":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial","volume":"27","author":"Einsele","year":"2026","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.clml.2026.07.009_bib0007","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.3390\/cancers13205154","article-title":"Relapsed\/refractory multiple myeloma in 2020\/2021 and beyond","volume":"13","author":"Podar","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.clml.2026.07.009_bib0008","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","article-title":"FDA approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2026.07.009_bib0009","article-title":"Investigating CAR-T treatment access for multiple myeloma patients using real-world evidence","author":"Davidson","year":"2025","journal-title":"medRxiv"},{"issue":"18","key":"10.1016\/j.clml.2026.07.009_bib0010","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1182\/bloodadvances.2024015634","article-title":"Inequalities in CAR T-cell therapy access for US patients with relapsed\/refractory DLBCL: a SEER-Medicare data analysis","volume":"9","author":"Chung","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.009_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2023.11846","article-title":"Fair allocation of scarce CAR T-cell therapies for relapsed\/refractory multiple myeloma","author":"Derman","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.clml.2026.07.009_bib0012","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.clml.2024.06.011","article-title":"Improving access to T-cell therapies in multiple myeloma","volume":"24","author":"Derman","year":"2024","journal-title":"Clin Lymph Myel Leuk"},{"key":"10.1016\/j.clml.2026.07.009_bib0013","unstructured":"Cancer facts & figures for African American\/black people. Accessed: December 2, 2025. Available at: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/cancer-facts-figures-for-african-americans.html."},{"issue":"25","key":"10.1016\/j.clml.2026.07.009_bib0014","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.07.009_bib0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-020-0284-7","article-title":"Dissecting racial disparities in multiple myeloma","volume":"10","author":"Marinac","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2026.07.009_bib0016","article-title":"Multiple myeloma incidence and mortality trends in the United States, 1999\u20132020","volume":"14","author":"Zhu","year":"2024","journal-title":"Sci Rep"},{"issue":"20","key":"10.1016\/j.clml.2026.07.009_bib0017","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","article-title":"Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis","volume":"3","author":"Ailawadhi","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2026.07.009_bib0018","first-page":"163","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut Med"},{"issue":"2","key":"10.1016\/j.clml.2026.07.009_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.bict.2025.100007","article-title":"Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma","volume":"1","author":"Paruzzo","year":"2025","journal-title":"Blood Immunol Cell Ther"},{"issue":"5","key":"10.1016\/j.clml.2026.07.009_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.10670","article-title":"Travel-time disparities in access to proton beam therapy for cancer treatment","volume":"7","author":"Burus","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.clml.2026.07.009_bib0021","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1016\/j.clml.2023.08.008","article-title":"Disparities in multiple myeloma treatment patterns in the United States: a systematic review","volume":"23","author":"Gasoyan","year":"2023","journal-title":"Clin Lymph Myel Leuk"},{"key":"10.1016\/j.clml.2026.07.009_bib0022","unstructured":"Patient Insights | the Komodo Platform. Komodo Health. Accessed November 14, 2025. Available at: https:\/\/www.komodohealth.com\/komodo-patient-insights\/."},{"issue":"9596","key":"10.1016\/j.clml.2026.07.009_bib0023","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"Von","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.07.009_bib0024","unstructured":"Bureau UC. American Community Survey (ACS). Census.gov. Accessed December 8, 2025. Available at: https:\/\/www.census.gov\/programs-surveys\/acs.html."},{"key":"10.1016\/j.clml.2026.07.009_bib0025","unstructured":"USCS Data visualizations. Accessed December 8, 2025. Available at: https:\/\/gis.cdc.gov\/grasp\/USCS\/DataViz.html."},{"key":"10.1016\/j.clml.2026.07.009_bib0026","unstructured":"Find a treatment center - ABECMA\u00ae (idecabtagene vicleucel). Accessed November 14, 2025. Available at: https:\/\/www.abecma.com\/find-a-treatment-center."},{"key":"10.1016\/j.clml.2026.07.009_bib0027","unstructured":"Official Patient Website | CARVYKTI\u00ae (ciltacabtagene autoleucel). Official CARVYKTI patient website. Accessed November 14, 2025. Available at: https:\/\/www.carvykti.com\/treatment-centers."},{"key":"10.1016\/j.clml.2026.07.009_bib0028","unstructured":"Mapbox | Maps, Navigation, search, and data. Accessed November 14, 2025.Available at: https:\/\/www.mapbox.com."},{"key":"10.1016\/j.clml.2026.07.009_bib0029","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.semcancer.2023.04.003","article-title":"Obesity and multiple myeloma: emerging mechanisms and perspectives","volume":"92","author":"Tentolouris","year":"2023","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"10.1016\/j.clml.2026.07.009_bib0030","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyaf188","article-title":"Neighborhood disadvantage and multiple myeloma incidence in the Black Women\u2019s Health Study","volume":"54","author":"Holder","year":"2025","journal-title":"Int J Epidemiol"},{"issue":"9","key":"10.1016\/j.clml.2026.07.009_bib0031","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.3109\/10428194.2015.1011156","article-title":"Socioeconomic status is independently associated with overall survival in patients with multiple myeloma","volume":"56","author":"Fiala","year":"2015","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.clml.2026.07.009_bib0032","unstructured":"CDC. PLACES: local data for better health. 2025. Accessed December 8, 2025. Available at: https:\/\/www.cdc.gov\/places\/index.html."},{"key":"10.1016\/j.clml.2026.07.009_bib0033","unstructured":"Rural-urban commuting area codes | economic research service. Accessed December 8, 2025. Available at: https:\/\/www.ers.usda.gov\/data-products\/rural-urban-commuting-area-codes."},{"issue":"7","key":"10.1016\/j.clml.2026.07.009_bib0034","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"23","key":"10.1016\/j.clml.2026.07.009_bib0035","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1002\/cam4.4797","article-title":"Demographic differences among patients treated with chimeric antigen receptor T-cell therapy in the United States","volume":"11","author":"Emole","year":"2022","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.clml.2026.07.009_bib0036","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1200\/JCO.2016.68.3805","article-title":"Association between treatment facility volume and mortality of patients with multiple myeloma","volume":"35","author":"Go","year":"2017","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.clml.2026.07.009_bib0037","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clml.2023.09.009","article-title":"Overall survival in patients with multiple myeloma in the U.S.: a systematic literature review of racial disparities","volume":"24","author":"Mikhael","year":"2024","journal-title":"Clin Lymph Myel Leuk"},{"issue":"6","key":"10.1016\/j.clml.2026.07.009_bib0038","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3324\/haematol.2023.282788","article-title":"Real-world multiple myeloma risk factors and outcomes by non-Hispanic black\/African American and non- Hispanic white race\/ethnicity in the United States","volume":"109","author":"Buck","year":"2024","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2026.07.009_bib0039","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1007\/s12325-021-01838-z","article-title":"Access to chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma","volume":"38","author":"Snyder","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2026.07.009_bib0040","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.1182\/blood-2024-207882","article-title":"Social determinants of health (SDOH) and access to CART for Multiple myeloma","volume":"144","author":"Weise","year":"2024","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:35:42Z","timestamp":1793694942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026002144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2152265026002144"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Geographic Variation and Inequities in Burden and Access to CAR T-Cell Therapies for Multiple Myeloma in the US","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}